Tribal sovereign immunity does not apply to inter partes review proceedings, the US Patent and Trademark Office’s (USPTO’s) Patent Trial and Appeal Board (PTAB) has determined. The finding came as the board dismissed the Saint Regis Mohawk Tribe’s motion to terminate challenges from Akorn, Mylan and Teva to six US patents shielding the Restasis (cyclosporine) brand that Allergan controversially sold to the Tribe last year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?